<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567473</url>
  </required_header>
  <id_info>
    <org_study_id>CTO 1423</org_study_id>
    <nct_id>NCT03567473</nct_id>
  </id_info>
  <brief_title>Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study</brief_title>
  <acronym>BIPED</acronym>
  <official_title>A Randomized Controlled Trial Comparing Epinephrine and Dexamethasone to Placebo in the Treatment of Infants With Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Research Institute of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women and Children's Health Research Institute, University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatrics, Western University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Eastern Ontario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that infants with bronchiolitis treated with inhaled epinephrine in the&#xD;
      Emergency Department (ED) and a 2-day course of oral dexamethasone will have fewer&#xD;
      hospitalizations over 7 days compared to infants treated with placebo. To examine this&#xD;
      hypothesis, we will conduct a phase III, multicentre, randomized, double-blind trial. Infants&#xD;
      presenting to one of twelve study EDs will be enrolled to one of two study groups: (1)&#xD;
      inhaled epinephrine and oral dexamethasone or (2) inhaled placebo and oral placebo. Our&#xD;
      primary outcome will be admission for bronchiolitis by day 7 following the enrolment. As a&#xD;
      planned secondary analysis, a between-group comparison of the primary outcome will be&#xD;
      performed in those patients presenting with a first episode of bronchiolitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All study personnel (including study nurses, coordinators, investigators, data management staff, and statistical team), health care staff providing patient care, and patients/families will be blinded to the study group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Admission to hospital for bronchiolitis within 7 days post enrollment</measure>
    <time_frame>7 days post enrollment</time_frame>
    <description>1) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission to hospital for bronchiolitis at the time of the enrollment ED visit</measure>
    <time_frame>Enrollment visit</time_frame>
    <description>1) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause admission to Hospital within 21 days following enrollment ED visit</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>1) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause Health care provider visits (including ED visits) by day 21 following enrollment ED</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care related costs within the 21 days following enrollment ED visits.</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>Health care related costs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome 1: Gastrointestinal bleeding</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>involving melena or frank blood per rectum (and not attributable to other causes, as determined by the treating physician)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety outcome 2: Serious Bacterial Infection</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>meningitis, osteomyelitis or septicaemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety outcome 3: Severe Varicella</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>All of the following including: arthritis, osteomyelitis, symptomatic hepatitis, pancreatitis, cerebritis, pneumonitis, glomerulonephritis, disseminated intravascular coagulation, thrombo-cytopenia, prolonged vesicular rash (&lt;3 weeks), fasciitis, septicaemia, ocular complications, orchitis, myocarditis, intensive care admission and death</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety outcome 4: Death</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>Death</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 1: Admission to hospital for bronchiolitis within 21 days following enrollment ED visit</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>1) Patient admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 2: Admission to ICU within 21 days following enrollment ED visit for bronchiolitis and requiring intubation or continuous positive airway pressure (CPAP)</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>Physician admitting patient to ICU for bronchiolitis and requiring oxygen or ventilatory support</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 3: All cause admission to hospital with 7 days following enrollment ED visit</measure>
    <time_frame>up to 7 days post enrollment ED visit</time_frame>
    <description>1) Patient admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 4: All cause ED visits within 21 days following enrollment ED visit</measure>
    <time_frame>up to 21 days post enrollment ED</time_frame>
    <description>Visits to the ED after initial enrollment ED visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 5: Length of stay for the enrollment ED visit (in hours)</measure>
    <time_frame>Enrollment ED visit</time_frame>
    <description>defined as discharge time minus oral study medication time, for participants discharged at the enrollment ED</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 6: Length of hospital admission for those patients admitted at their enrollment visit</measure>
    <time_frame>Admissions at enrollment ED visit</time_frame>
    <description>time of hospital discharge minus the time of oral study medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 7: Resolution of symptoms as documented on a standardized questionnaire during the telephone or email at day 7 and 21 days.</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>cough, noisy breathing, respiratory distress, sleep and ability to feed</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 8: Out of pocket expenses</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>transportation, days of missed work, missed leisure activities</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 9: Age dependent variation in the efficacy of epinephrine and dexamethasone</measure>
    <time_frame>up to 21 days post enrollment</time_frame>
    <description>to determine if treatment efficacy varies by age</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 10: Health care utilization (including ambulatory visits, ED visits, hospitalization) for respiratory illness</measure>
    <time_frame>Up to 18 years of age</time_frame>
    <description>future health care utilization</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Outcome 11: Development of respiratory illnesses</measure>
    <time_frame>Up to 18 years of age</time_frame>
    <description>asthma, wheezing and other respiratory illnesses</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1616</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>Active Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.&#xD;
OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral dexamethasone</intervention_name>
    <description>Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later</description>
    <arm_group_label>Active Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Epinephrine</intervention_name>
    <description>Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment</description>
    <arm_group_label>Active Intervention Arm</arm_group_label>
    <other_name>Nebulized Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized normal saline</intervention_name>
    <description>Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDI Epinephrine</intervention_name>
    <description>Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.</description>
    <arm_group_label>Active Intervention Arm</arm_group_label>
    <other_name>MDI Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDI placebo</intervention_name>
    <description>Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presenting to the ED with an episode of bronchiolitis. Bronchiolitis will be defined&#xD;
             as an episode of wheezing or crackles in a child &lt; 12 month of age associated with&#xD;
             signs of an upper respiratory tract infection (e.g. cough, coryza, nasal congestion)&#xD;
             during the period deemed to be peak season for RSV bronchiolitis (approximately&#xD;
             December to April in Northern Hemisphere and June to October in Southern Hemisphere).&#xD;
             We have chosen not to define bronchiolitis as the first episode of wheezing or&#xD;
             crackles to better reflect the clinical guidelines and clinical practice&#xD;
             internationally.&#xD;
&#xD;
          2. Age 60 days to less than 12 months. Children younger than 60 days will not be enrolled&#xD;
             due to the risk of concomitant infection and other issues pertaining to glucocorticoid&#xD;
             use in the very young. Children older than 12 months will not be enrolled to minimize&#xD;
             the risk of enrolling children with asthma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Respiratory distress assessment instrument (RDAI) score of less than or equal to 3.&#xD;
             This RDAI will ensure children with very mild respiratory diseases are not enrolled.&#xD;
             This is the lower limit of the RDAI range used in CanBEST.&#xD;
&#xD;
          2. Previously known chronic disease that may affect cardiopulmonary status of the&#xD;
             patient, such as bronchopulmonary dysplasia currently receiving oxygen, cystic&#xD;
             fibrosis, congenital heart disease and immune deficiency. These children may be at&#xD;
             higher risk for developing severe illness.&#xD;
&#xD;
          3. Severe respiratory distress evidenced by a sustained pulse rate &gt; 200 beats/min, a&#xD;
             sustained respiratory rate &gt; 80 breaths/min, profound lethargy (as deemed by the&#xD;
             treating physician), or requiring resuscitation room care. We will exclude these&#xD;
             children as they are likely to be admitted due to severity of illness.&#xD;
&#xD;
          4. Presenting with symptoms of apnea prior to enrollment.&#xD;
&#xD;
          5. Treatment with oral, inhaled, or IV corticosteroids within the last 1 week.&#xD;
&#xD;
          6. History of adverse reaction to glucocorticoids.&#xD;
&#xD;
          7. Treatment with any beta-agonists (salbutamol/albuterol or epinephrine/adrenaline) in&#xD;
             the ED prior to study enrolment.&#xD;
&#xD;
          8. Presence of varicella or recent (less than 3 weeks) close contact (defined as any&#xD;
             household or daycare contact, or greater than 15 minutes of face to face contact, or&#xD;
             greater than 1 hour of being in the same dwelling with an individual) without a&#xD;
             history of prior infection. These patients are not enrolled to reduce any risk of&#xD;
             developing severe varicella with corticosteroid use.&#xD;
&#xD;
          9. Insurmountable language barrier (patient's parent/guardian is unable to understand&#xD;
             English or French to give informed consent and participate in follow-up).&#xD;
&#xD;
         10. Any child born at less than 37weeks gestation who is younger than 60 days corrected&#xD;
             age. We will not enroll these children to lower any risk of exposing young infants to&#xD;
             corticosteroids.&#xD;
&#xD;
         11. Previous enrolment in the trial.&#xD;
&#xD;
         12. Unavailability for follow-up period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Plint, MSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital of Eastern Ontario (CHEO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina I Vogel</last_name>
    <phone>613-737-7600</phone>
    <phone_ext>3348</phone_ext>
    <email>kvogel@cheo.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Candice McGahern</last_name>
    <phone>613-737-7600</phone>
    <phone_ext>4111</phone_ext>
    <email>CMcGahern@cheo.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women and Children's Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaby Nivea</last_name>
      <email>gaby.nieva@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Amit Kochar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Ramage</last_name>
      <email>emma.ramage@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Simon Craig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon O'brien</last_name>
      <email>Sharon.O'Brien@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Meredith Borland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Kim</last_name>
      <phone>403-955-5451</phone>
      <email>kelly.kim@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Graham Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mithra Sivakumar</last_name>
      <phone>780-492-0451</phone>
      <email>mithra@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital at London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Boisvert</last_name>
      <email>Leslie.Boisvert@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Gary Joubert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHEO</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tremaine Rowe</last_name>
      <phone>613-737-7600</phone>
      <phone_ext>3348</phone_ext>
      <email>trowe@cheo.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Candice McGahern</last_name>
      <phone>613-737-7600</phone>
      <phone_ext>4111</phone_ext>
      <email>CMcGahern@cheo.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Plint, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justines Hospital</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>HT3 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Auclair</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>3827</phone_ext>
      <email>marie.christine.auclair@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Serge Gouin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Winnipeg</name>
      <address>
        <city>Sherbrook</city>
        <state>Winnipeg</state>
        <zip>R3A 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Bourrier</last_name>
      <email>lbourrier@chrim.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Sawyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Bonisch</last_name>
      <email>MBonisch@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Stuart Dalziel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidz First Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shirley Lawrence</last_name>
      <email>shirley.lawrence@middlemore.co.nz</email>
    </contact>
    <investigator>
      <last_name>Jocelyn Neutze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Wallace</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Eastern Ontario</investigator_affiliation>
    <investigator_full_name>Amy Plint</investigator_full_name>
    <investigator_title>MD, MSc, FRCPC, Research Chair in Pediatric Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

